Development of a whole killed feline leukemia virus vaccine.
A whole killed FeLV vaccine was developed. By use of a chromatography method of purification and concentration, the resulting vaccine has been shown to be significantly lower in bovine serum albumin and total protein contents than were the same ingredients in the starting materials. The virus was inactivated or killed as an essential part of the vaccine development process. Vaccination trials with the vaccine without use of adjuvants indicated appreciable virus-neutralizing serum titer (greater than or equal to 1:10) in 107 of 110 vaccinated cats. Of 43 cats vaccinated and subsequently challenge exposed with virulent FeLV, only 2 developed persistent virus antigenemia (longer than 1 month), whereas 14 of 22 nonvaccinated control cats developed persistent viremia. In field tests, 2,770 cats from 6 states were vaccinated and observed. Postvaccinal reactions were not observed.
York
S M
SM
Bio-Trends International Inc, West Sacramento, CA 95691.
York
C J
CJ
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000097:blood; D002415:Cats; D002845:Chromatography; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D009500:Neutralization Tests; D015682:Retroviridae Proteins, Oncogenic / Q000032:analysis* / Q000276:immunology / Q000592:standards; D014611:Vaccination / Q000662:veterinary*; D015164:Vaccines, Inactivated / Q000032:analysis / Q000276:immunology / Q000592:standards; D014765:Viral Vaccines / Q000032:analysis* / Q000276:immunology / Q000592:standards; D014766:Viremia / Q000517:prevention & control / Q000662:veterinary
D000914:Antibodies, Viral; D000956:Antigens, Viral; D015682:Retroviridae Proteins, Oncogenic; D015164:Vaccines, Inactivated; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine